

**Question for written answer E-000745/2024
to the Commission
Rule 138
Adam Jarubas (PPE)**

Subject: Pancreatic cancer

In 2021, we welcomed Europe's Beating Cancer Plan. This created momentum for action, which needs to be sustained. Some cancers are better known than others, and some require extra care and attention, including from policymakers. Pancreatic cancer is one of the most lethal forms of cancer and is the fourth largest cause of cancer death in Europe. Despite its significant public health impact, effective treatments exist only for early cancers, where complete surgical resection is possible. There are not enough high-profile research efforts to improve care. Pancreatic cancer has the lowest rate of survival of all cancers across Europe, killing about 92 % of patients within five years of diagnosis. When diagnosed, 80 % of patients already have tumours that are at too late a stage to be cured. The five-year survival rate for pancreatic cancer is below 8 %. European funding can provide desperately needed advances in this area.

1. What steps is the Commission undertaking to support effective approaches to and treatment of pancreatic cancer?
2. How is the Commission planning to ensure that an appropriate level of funding and support is maintained for pancreatic cancer research and care?

Submitted:8.3.2024